Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Return on Equity (2016 - 2025)

Viking Therapeutics' Return on Equity history spans 11 years, with the latest figure at 0.53% for Q4 2025.

  • For Q4 2025, Return on Equity fell 41.0% year-over-year to 0.53%; the TTM value through Dec 2025 reached 0.53%, down 41.0%, while the annual FY2025 figure was 0.47%, 29.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.53% at Viking Therapeutics, down from 0.31% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.1% in Q2 2024 and bottomed at 0.53% in Q4 2025.
  • The 5-year median for Return on Equity is 0.24% (2021), against an average of 0.27%.
  • The largest annual shift saw Return on Equity skyrocketed 37bps in 2024 before it tumbled -41bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.26% in 2021, then tumbled by -75bps to 0.46% in 2022, then soared by 48bps to 0.24% in 2023, then skyrocketed by 49bps to 0.12% in 2024, then plummeted by -333bps to 0.53% in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Return on Equity are 0.53% (Q4 2025), 0.31% (Q3 2025), and 0.21% (Q2 2025).